Regeneron: FY2022 EYLEA US sales $6.26B (+8%), Q4 $1.50B (-3%); expects $30M IPR&D charge

REGENERON PHARMACEUTICALS, INC.

FY2022 EYLEA US net product sales ~$6.26B (+8% YoY); Q4 2022 ~$1.50B (-3% YoY).
Q4 EYLEA negatively impacted by short-term shift to off-label compounded Avastin and temporary closure of co-pay assistance fund; reversal beginning per Dec 2022 market data.
Expects ~$30M IPR&D charge from CytomX collaboration, reducing Q4 2022 GAAP/non-GAAP diluted EPS by ~$0.21.
Aflibercept 8 mg BLA submitted for wAMD and DME using priority review voucher; potential FDA approval by late August 2023.
Dupixent approved in 2022 for AD infants (6mo-5yr), EoE, prurigo nodularis; sBLA submitted for CSU in biologic-naïve patients.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENERON PHARMACEUTICALS, INC. reported full year 2022 results: revenue approximately $6.26 billion.

Period: full year 2022
Revenue: approximately $6.26 billion
Result: preliminary results

Exact text from the filing

The presentation includes information regarding the Company’s preliminary (unaudited) U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $6.26 billion for the full year 2022 (based on preliminary (unaudited) fourth quarter 2022 U.S. net product sales of EYLEA of approximately $1.50 billion).

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-002091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.